Sagent-Hengrui Partnership Launches Second Cancer Drug in US

Sagent Pharma announced the second US launch of a product from its partnership with Hengrui Medicine . The drug is Oxaliplatin Injection, USP, a treatment for colon and rectal cancer, which has a US market of $102 million, according to IMS. Hengrui will manufacture the drug. Last month, Sagent began US marketing of Hydrochloride Injection, another Hengrui-produced treatment for cancer.  More details.... Stock Symbols: (NSDQ: SGNT) (SHA: 600276) Share this with colleagues: // //